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Abstract
Squamous cell carcinoma of the conjunctiva is associated with a number of risk factors, including HIV infection, iatrogenic
immunosuppression and atopy. In addition, several studies have suggested an involvement of HPV, based on the presence of
viral DNA, but did not establish whether there was active infection or evidence of causal disease association. In this
manuscript, 31 cases of conjunctival in situ squamous cell carcinoma were classified as HPV DNA-positive or -negative,
before being analysed by immunohistochemistry to establish the distribution of viral and cellular biomarkers of HPV gene
expression. Our panel included p16INK4a, TP53 and MCM, but also the virally encoded E4 gene product, which is
abundantly expressed during productive infection. Subsequent in situ detection of HPV mRNA using an RNAscope
approach confirmed that early HPV gene expression was occurring in the majority of cases of HPV DNA-positive
conjunctival in situ squamous cell carcinoma, with all of these cases occurring in the atopic group. Viral gene expression
correlated with TP53 loss, p16INK4a elevation, and extensive MCM expression, in line with our general understanding of E6
and E7’s role during transforming infection at other epithelial sites. A characteristic E4 expression pattern was detected in
only one case. HPV mRNA was not detected in lower grades of dysplasia, and was not observed in cases that were HPV
DNA-negative. Our study demonstrates an active involvement of HPV in the development of a subset of conjunctival in situ
squamous cell carcinoma. No high-risk HPV types were detected other than HPV16. It appears that the conjunctiva is a
vulnerable epithelial site for HPV-associated transformation. These cancers are defined by their pattern of viral gene
expression, and by the distribution of surrogate markers of HPV infection.
Introduction
The conjunctival epithelium can give rise to squamous
dysplasia, carcinoma in situ and invasive squamous carci-
noma. Two disease patterns occur. The first shows an
incidence that is highest in the Southern Hemisphere
(16° South), particularly in Africa, with a mean age of 40
years. Elsewhere, conjunctival squamous neoplasia affects
older adults with a mean age of occurrence at around 60
years, and is found more often in men (70%) than women.
The Age Standardised Rate (ASR) worldwide is 0.18 and
0.08 cases/year/100,000 among males and females respec-
tively, but can be as high as 19 cases/year/100,000 in some
locations [1]. Lifelong exposure to ultraviolet light is con-
sidered to be the major aetiological factor in the develop-
ment of conjunctival squamous neoplasia, along with
outdoor occupations. Meta-analysis has also shown an
association with HIV and HPV, iatrogenic immunosup-
pression post-organ transplantation, as well as atopic
* John Doorbar
jd121@cam.ac.uk
1 Department of Pathology, University of Cambridge, Tennis Court
Road, Cambridge CB2 1QP, UK
2 National Specialist Ophthalmic Pathology Service, Department of
Histopathology, E-Floor, Royal Hallamshire Hospital, Glossop
Rd, Sheffield S10 2JF, UK
3 Sheffield Ocular Oncology Service, Department of
Ophthalmology, Royal Hallamshire Hospital, Glossop Rd,
Sheffield S10 2JF, UK
4 Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill
Hill, London NW7 1AA, UK
5 Delft Diagnostic Laboratories, Visseringlaan 25, 2288 ER
Rijswijk, The Netherlands
eczema but not cigarette smoking. The effect of Xeroderma
pigmentosum and vitamin A deficiency is unclear [2].
African women probably have increased risk of conjunctival
squamous neoplasia due to the higher prevalence of HIV and
HPV infections. It is generally expected that the incidence of
conjunctival squamous neoplasia will increase in coming
years, as anti-retroviral therapy does not impact on the
disease incidence, and because the number of individuals
living with HIV infections will increase. A contributory role
of atopy in the development of conjunctival squamous
neoplasia has also been suggested [3]. The appearance of
conjunctival squamous neoplasia in asthmatic individuals
occurs at a younger age than normally expected, is more
likely to occur bilaterally and is generally more aggressive.
The human papillomaviruses (HPV) are a large and het-
erogeneous group of small non-enveloped DNA viruses that
complete their life cycle in a range of different epithelial
tissues. They are often referred to as either low- or high risk
depending on their tumourogenic potential. Cervical cancer
is the most prevalent cancer caused by high-risk HPV (HR-
HPV), but HPV-associated cancers also occur at other vul-
nerable epithelial sites, including the anus and oropharynx.
Papillomaviruses display an extreme level of adaptation to
the regulatory mechanisms governing keratinocyte differ-
entiation, with viral genes being sequentially activated dur-
ing this process [4]. Thus the HR-HPV E6 and E7 gene
products stimulate cell proliferation in the lower epithelial
layers, but also ensure that differentiating cells undergo cell
cycle entry to facilitate viral genome amplification in the
upper epithelial layers [4, 5]. Viral proteins involved in
replication and transmission, such as E4, accumulate in these
differentiating cells to support virus assembly and the
eventual release of infectious virions from the superficial cell
layers [4]. Our current thinking suggest that the levels and
activity of E6 and E7 are tightly regulated in such productive
infections, where basaloid cells occupy the lower third of
epithelium, but can become deregulated in high-grade
squamous-intraepithelial lesions or moderate to severe dys-
plasia [5]. Viral gene expression underlies the pathology of
both low- and high-grade cervical squamous-intraepithelial
lesions, and can predispose the infected cell to the accu-
mulation of genetic errors and the eventual progression to
cancer [5]. These effects are a consequence of E6 and E7’s
interaction with a plethora of host-encoded proteins, of
which TP53 and members of the pRb pocket protein family
are most thoroughly characterised [6, 7]. When expressed
together, host cell proteins that are normally regulated by
pRb, including p16INK4a, MCM (minichromosome main-
tenance), and Ki-67, can be used as surrogate markers of
viral gene expression [6–8], and are expressed throughout
the epithelial layers in high-grade cervical neoplasia and
cancer [9, 10]. In low-grade cervical lesions, such proteins
are typically confined to the lower epithelial layers.
Although HR-HPV DNA has been reported to be present
in dysplastic and malignant lesions of the conjunctiva and
lacrimal sac, the presence of viral DNA does not necessarily
confirm an active role for the virus as the cause of the
lesion. HPV DNA detection is often combined with
immunohistochemistry for p16INK4a and/or Ki-67 [11–14],
although these markers can also be detected in cells
undergoing metaplasia and senescence. Here we combine
standard HPV DNA typing, with immunohistochemistry
and an in situ mRNA staining technique able to detect HPV-
E6 and -E7 gene expression in biopsies taken from patients
either with conjunctival in situ squamous carcinoma, and
with lower grade dysplasia, in order to clarify the role of
HPV in conjunctival squamous neoplasia. Our data reveal
that a subset of conjunctival in situ squamous carcinomas
have a clear HPV involvement, with a deregulated pattern
of HPV gene expression comparable with that seen in high-
grade squamous-intraepithelial lesions at other sites. Only in
one of the conjunctival in situ squamous carcinoma cases
examined was there evidence of productive infection and
the expression of E4, suggesting that the corneal limbus and
conjunctiva are primarily sites of abortive HPV infection.
This study confirms that the conjunctiva is one of the vul-
nerable epithelial sites where high-risk HPV infection can
lead to the development of precancerous lesions.
Materials and methods
Clinical samples
Conjunctival biopsies with a diagnosis of in situ squamous
carcinoma, and lower grades of squamous dysplasia, were
obtained from the National Specialist Ophthalmic Pathol-
ogy Service Histopathology archive from the Royal Hal-
lamshire Hospital, Sheffield. These diagnostic biopsies were
performed as part of the routine clinical management of
patients presenting with a mass on the conjunctiva. Biopsies
were fixed in standard 10% buffered formalin and processed
to paraffin. Four micrometre sections were cut and stained
with standard haematoxylin and eosin for conventional light
microscopic diagnostic interpretation. Additional sections
were used for in situ hybridisation, immunohistochemistry
or immunofluorescence analysis; with three sections taken
for whole tissue section-PCR HPV genotyping (as descri-
bed previously [14]). To avoid cross-contamination, a fresh
new disposable blade was used for sectioning, and the
microtome was cleaned between each block using DNAzap.
All protocols were approved by local ethics committees
(Study approved by Sheffield Teaching Hospitals clinical
research office under the Ophthalmology tissue bank,
number STH15427 with sub study numbers: STH18647 and
STH19306).
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Clinical information
Relevant patient clinical information was obtained from the
clinical records, from the Department of Ophthalmology,
Royal Hallamshire Hospital Sheffield. This included the
age, sex, side of tumour, the precise conjunctival location,
clinical appearance, the primary treatment modality and the
recurrence rate and responses to treatment. The presence or
absence of atopic conditions (asthma and eczema) was
established at the time of the clerking of the patient during
their ocular oncology clinic visit, and cross referenced with
dermatology and respiratory clinical entries in the hospital
clinical notes. These various clinical parameters are sum-
marised in Table 1.
Histopathologic review
All primary diagnostic histopathology evaluations were
based on the haematoxylin and eosin-stained slides. All
cases were reported and reviewed by a single ocular
pathologist (HSM). The most recent World Health Orga-
nisation criteria for grading conjunctival squamous epithe-
lial dysplasia was used in this study [15]. Mild dysplasia is
confined to the lower third of the epithelium; moderate
dysplasia extends to the middle third of the epithelium;
severe dysplasia involves the upper third of the epithelium
with retention of surface maturation and in situ squamous
carcinoma is full-thickness replacement with dysplastic
epithelial cells.
HPV DNA detection and typing
HPV typing was carried out at two expert diagnostic cen-
tres, which we have previously found to produce compa-
tible typing data. Cases 1–30 were analysed at the Scottish
HPV Reference Laboratory, Edinburgh, for the presence of
HPV DNA. Nucleic acid extraction using the reagents
within the DNA mini kit (Qiagen, Hilden, Germany) with a
protocol adapted to maximise HPV nucleic acid recovery.
DNA extracts were tested for HPV using the Optiplex HPV
Genotyping Kit (Diamex GmbH, Heidelberg, Germany).
This genotyping test detects 24 HPV types including all
established high-risk types 6, 11,16, 18, 26, 31, 33, 35, 39,
42, 43, 44, 45, 51, 52, 53,56, 58, 59, 66, 68, 70, 73 and 82).
For cases 31–41 (15 biopsies), DNA detection was per-
formed at DDL HPV laboratories by PCR amplification
with SPF-10 broad-spectrum primers followed by a reverse
hybridisation line probe assay, LiPA25 (version 1,
Laboratory Biomedical Products, Rijswijk, the Nether-
lands). LiPA25 enables simultaneous detection of indivi-
dual 25 high-risk and low-risk HPV types (6, 11, 16, 18, 31,
33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59,
66, 68, 70, and 74) [14].
Immunohistochemical/fluorescent staining and
image analysis
The HPV E4 protein was detected using the synthetic single
chain antibody TVG405 [16], or the mouse cross-reactive
E4 monoclonal antibody FH1.1 [17]. The cellular MCM,
p16INK4a and TP53 proteins were detected by immunohis-
tochemistry or immunoflourescence on conjunctival biop-
sies and raft sections using previously described protocols
[18]. Alexa-488 labelled TVG405 (10 μg/ml IgG) was
diluted 1/150 prior to use, while FH1.1 (1 mg/ml IgG) was
diluted 50-fold. Anti-MCM (rabbit monoclonal ab52489,
Abcam, Cambridge, UK) was diluted 100-fold, TP53
(mouse monoclonal D01 Santa Cruz Biotechnology, Dallas,
Texas, USA) was diluted 1/300. Antibody binding was
visualised using anti-mouse or anti-rabbit Alexa Fluor 488-
or 594-conjugated secondary antibodies (Invitrogen−Ther-
moFisher) diluted 150-fold. Nuclei were counterstained
with DAPI. Immunofluorescence images were scanned
using a digital slide scanner (3DHistech, Budapest, Hun-
gary), before the sections were then stained with haema-
toxylin and eosin and scanned again. P16INK4a
immunohistochemistry was performed using the pre-diluted
monoclonal mouse anti-human antibody clone E6H4, sup-
plied as part of the CINtec Histology kit (CINtec Ref 9512
Roche). After amplification with a dextran polymer con-
jugated to HRP, slides were developed using DAB and
counterstained with haematoxylin according to the manu-
facturers’ instructions. Sections of cervical high-grade
squamous-intraepithelial lesions were used as antibody
positive controls. Normal (uninfected) cervical tissue, and
HPV-negative organotypic raft material were used as
p16INK4a negative controls.
Quantification of immunohistochemistry and
immunofluorescence data
P16INK4a immunostaining was classified using the conven-
tion previously established for the classification of low- and
high-grade HPV-associated neoplasia at other epithelial
sites [17]. Tissue sections were graded into three groups,
depending on whether p16INK4a positivity was (1) absent or
focal; (2) diffuse but restricted to the lower third of the
epithelium; (3) diffuse in the lower third of the epithelium,
but extending also into the upper epithelial layers. Such
lesions included those in which the p16INK4a staining
occurred throughout the full thickness of the epithelium.
MCM scoring was similarly based on approaches used to
classify other HPV-associated neoplasia. In this case,
grading indicated whether MCM was (1) confined to the
basal and parabasal layers only; (2) diffuse but restricted to
the lower third of the epithelium; (3) diffuse in the lower
third of the epithelium, but extending also into the upper
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epithelial layers, including full thickness. TP53, which is
depleted in cells supporting HR HPV gene expression [19],
was more difficult to classify using a simple scaling scheme.
TP53 staining is described according to its location and
extent throughout the thickness of the epithelium.
In situ detection of HPV transcription using
RNAscope assay
In situ hybridisation for HPV16-specific RNA was performed
manually using the RNAscope 2.5 assay HPV kit (Advanced
Cell Diagnostics Inc., Hayward, CA), with the HPV 16 E6/E7
probe (Cat. Number 311521), according to the manufacturer’s
instructions. Sections were counterstained with the nuclear
stain haematoxylin and were recorded as either positive or
negative. Positive cases had prominent granular cytoplasmic
and/or nuclear staining when compared with negative control
tissue. The integrity of RNA, and the suitability for HPV
transcriptional analysis was confirmed in each tissue section
using the control probe Pol2A, which detects housekeeping
gene expression (Cat. No 310451). An HPV-positive orga-
notypic raft was used as a positive control for the expression
of E6/E7 [20] while an HPV-negative organotypic raft was
used as a negative control (data not shown).
Results
Clinical features of conjunctival in situ squamous
carcinoma and lower grades of dysplasia
The study comprised 16/41 (39%) females and 25/41 (61%)
males (see Table 1). The female age range was 21−87y and
the male age range was 36−103y. Of the unilateral eyes
affected, there were 12/41 (30%) left eyes and 24/41 (58%)
right eyes. 5/41 (12%) bilateral cases were recorded. Cases
1−31 comprised those affected by conjunctival in situ
squamous carcinoma and cases 32−41 by lower grades of
dysplasia. In cases 1−31, there were 16 atopes (cases 1–16)
and 15 non-atopes (cases 17–31). Of the atopes there were
six affected by asthma and eczema, two with asthma alone
and eight with eczema alone. Cases 32−41 comprised cases
affected by lower grades of squamous dysplasia. Of this
group, two were atopic and eight non-atopic.
In cases 1−16 (atope group with in situ squamous
carcinoma), there was a strong trend for the medial/
inferomedial bulbar conjunctiva, inferior fornix and
inferior tarsal conjunctiva to be affected (14/16 cases) and
the clinical appearance of the tumour was red gelatinous
or papillomatous (12/16) (see Fig. 1a). In cases 17−31
(non-atope group with in situ squamous carcinoma), the
trend was mainly a medial limbal distribution (12/15) and
8/15 had a leukoplakic appearance (see Fig. 1b). In the
atope group (cases 1−16), 4/16 had bilateral disease,
compared to the non-atope group (cases 17–31) which
showed 1/15 bilateral cases. Although HPV testing was
not carried out in biopsies from both eyes, the course of
disease in each eye was the same. In cases 32−41 (lower
grades of dysplasia) there was no particular trend in the
location of the tumour, although 6/10 cases had a leuko-
plakic clinical appearance.
In cases 1−16 (atope group) 10/16 cases showed clinical
evidence of resistance to treatment; this comprised either
progression of disease during treatment (i.e. increase in size
of tumour or new tumour foci appearing) or persistent
disease where the size of the tumour was controlled by
continuous treatment. In the same group, 12/16 showed
evidence of recurrence clinically, which was confirmed by
histology. In contrast, within cases 17−31 (non-atope
group) there was no resistance to primary treatment and
only 4/15 cases recurred. In cases 32−41 (lower grades of
dysplasia group), there was no resistance to primary treat-
ment and only 3/10 cases recurred.
Fig. 1 Conjunctival carcinoma in situ; disease morphology. An
example of an HPV DNA-positive lesion arising at the medial bulbar
conjunctiva is shown in (a). The full clinical record notes this case as:
Left eye: papilleroid, non-leukoplakic, red gelatinous in situ squamous
cell carcinoma affecting the medial bulbar conjunctiva, plica, inferior
fornix and inferomedial tarsal conjunctiva. An HPV DNA-negative
tumour arising at the medial limbal conjunctiva is shown in (b). The
full clinical record notes this case as: Left eye: Leukoplakic solitary
raised nodule of keratinising in situ squamous cell carcinoma at the
medial limbal conjunctiva with medial cornea extension, with tumour
feeder vessels. Clinical details of all the tumours examined in this
study are listed in Table 1
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Detection of HPV DNA in conjunctival in situ
squamous carcinoma and lower grades of dysplasia
Biopsies from the 31 cases diagnosed histologically with
conjunctival in situ squamous cell carcinoma were further
examined in order to investigate the possible involvement
of HPV. 13/31 of the cases (42%) were HPV 16 DNA-
positive by RT-PCR/line probe assay, while 18 (58%)
were found to be HPV DNA-negative. All 13 HPV DNA-
positive biopsies contained HPV16 as the only papillo-
mavirus type that was present. Patients with HPV DNA-
positive in situ squamous carcinoma were all (13/13)
found to have an established history of atopy or allergic
hypersensitivity, including allergic asthma (2/13) and
atopic dermatitis (eczema; (8/13)), with three individuals
having a history of both. Of the 18 HPV-negative indi-
viduals, only 3 (17%) had been diagnosed with an atopic
condition (see Table 2). Ten cases of conjunctival biop-
sies that were classified as lower grades of dysplasia
following pathology analysis were also examined (see
section ‘Dysplasia’ in Table 2). Only four (out of 10
(40%)) of these were found to be HPV DNA-positive.
HPV type 16 was detected as a single HPV type in 4/4
cases, with HPV 6 (a low-risk HPV type) being found
along with HPV 16 in one sample. The remainder of the
group (6/10 (60%)) were HPV DNA-negative. In contrast
to the in situ squamous carcinoma group, biopsies taken
from the two atopic patients present in this second group
were HPV DNA-negative.
Classification of conjunctival in situ squamous
carcinoma and lower grades of dysplasia according
to gene expression and HPV status
HR-HPV causality is associated with defined changes in the
normal patterns of cellular gene expression within the epi-
thelium, which reflect the molecular processes that become
disrupted following virus infection. Most relevant is the loss
of TP53, which is mediated by the product of the HR-HPV
E6 gene, and the coexpression of cell cycle progression
markers such as MCM and Ki67, that are expressed along
with p16INK4a, a protein which would normally play a role
in growth arrest [21]. In HPV-driven high-grade squamous-
intraepithelial lesions, the cellular MCM, Ki67 and p16INK4a
proteins are induced by E7, leading to basal and parabasal
cell proliferation.
TP53 expression
The cellular TP53 protein was readily detectable in the basal
layers of normal conjunctival epithelium (inset in Fig. 2a), a
pattern which resembles our observations in normal cervical
tissue. In most of the HPV DNA-positive in situ squamous
carcinoma cases, TP53 was undetectable by immuno-
fluorescence microscopy (8/13 (62%)), as shown for cases 3
and 4 in Fig. 2a. The five remaining HPV DNA-positive
cases showed extensive TP53 expression throughout the full
thickness of the epithelium (Fig. 2b), a pattern suggesting
an absence of HPV E6 gene expression, which is discussed
more extensively below. The HPV DNA-negative in situ
squamous carcinoma cases were in general more hetero-
geneous with regard to TP53 expression. The majority (10/
17 (58%)) showed clear TP53 expression in the basal epi-
thelial layer, with some lesions sustaining expression into
the suprabasal cell layers, as shown for case 14 in Fig. 2c(i).
The remainder lacked TP53 expression in both the epithelial
basal layer and in the layers above, and in this regard, were
broadly similar to the HPV DNA-positive group (Fig. 2c
(ii)). Interestingly, of the five HPV DNA-positive in situ
squamous carcinoma cases that showed TP53 expression
throughout the epithelium, the three that stained positively
for p16INK4a were associated with widespread lymphocytic
infiltration (case 10 shown in Fig. 2b). It seems likely that
the local immune cell environment in these instances is
modulating both viral and cellular genes. Indeed, the
widespread TP53 and p16INK4a expression seen in case 10,
coupled with the low MCM expression (compare Fig. 2a,
b), suggests a lack of significant cell proliferation (senes-
cence) in this lesion at the time point examined, despite the
pathology-based diagnosis of in situ squamous carcinoma.
p16INK4a and MCM expression
In agreement with the above, most of the HPV DNA-
positive conjunctival in situ squamous carcinomacases
(other than case 10; Fig. 2) showed extensive MCM
expression throughout the epithelium, which was in contrast
to the more limited basal and mid layer staining seen in
many of the HPV DNA-negative cases. A similarly robust
nuclear and cytoplasmic p16INK4a distribution was also
apparent in the majority of the HPV DNA-positive con-
junctival in situ squamous carcinomacases (11/13 (85%),
Fig. 2a, b), which is reminiscent of what is seen in cervical
high-grade squamous-intraepithelial lesions [17]. Two of
the HPV DNA-positive cases (cases 12 and 13) showed
only focal, non-basal p16INK4a expression, which is a pattern
usually associated with senescence, and in these cases,
TP53 levels were also extensive. The combination of low
p16INK4a and high TP53 expression was unusual amongst
the HPV DNA-positive group, and was distinct from the
distribution seen during lymphocytic infiltration (cases 9, 10
and 11), suggesting that cases 12 and 13 may not be caused
by HPV, despite being HPV DNA-positive (see below).
Amongst the HPV DNA-negative in situ squamous carci-
noma group, most were also p16INK4a -negative (Table 2), in
line with our understanding of p16INK4a function, and the
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HPV RNA P16 MCM TP53 E4 Lymphocytic
infiltration
In situ squamous cell carcinoma
1 51F Asthma In situ SCC HPV 16 + 3 3 −ve (basal)
2 60M Asthma
and eczema
In situ SCC HPV 16 + 3 3 −ve (basal)
3 58M Asthma In situ SCC HPV 16 + 3 3 −ve (basal)
4 53F Eczema In situ SCC HPV 16 + 3 3 −ve (basal)
5 57M Eczema In situ SCC HPV 16 + 3 1 −ve (basal)
6 57F Eczema In situ SCC HPV 16 + 3 3 −ve (basal)
7 49F Asthma
and eczema
In situ SCC HPV16 + 3 3 −ve (basal)
8 76F Eczema In situ SCC HPV 16 + 3 3 −ve (basal) ✓
9 47M Eczema In situ SCC HPV 16 + 3 3 +ve (throughout) ✓
10 47M Eczema In situ SCC HPV 16 + 3 3 (weak) +ve (throughout) ✓
11 68M Asthma
and eczema
In situ SCC HPV 16 + 3 3 +ve (throughout) ✓
12 67M Eczema In situ SCC HPV 16 − 1 3 +ve (throughout)
13 45F Eczema In situ SCC HPV 16 − 1 3 +ve (throughout)
14 59F Asthma
and eczema
In situ SCC Negative − 1 1 +ve (throughout)
15 50M Asthma
and eczema
In situ SCC Negative ND 1 1 +ve (throughout)
16 57F Asthma
and eczema
In situ SCC Negative − 1 2 −ve (basal)
17 52F None In situ SCC Negative ND 1 3 +ve (throughout) ✓
18 87M None In situ SCC Negative ND 1 1 −ve (throughout)
19 103M None In situ SCC Negative ND 1 1 −ve (throughout)
20 82M None In situ SCC Negative ND 1 3 +ve
(throughout) (weak)
✓
21 94M None In situ SCC Negative ND 1 1 −ve (throughout)
22 36M None In situ SCC Negative ND 1 1 −ve (throughout)
23 71M None In situ SCC Negative ND 1 3 −ve (basal)
24 94M None In situ SCC Negative ND 1 1 +ve (basal)
25 81M None In situ SCC Negative − 3 3 +ve (throughout) ✓
26 88M None In situ SCC Negative − 2 3 +ve (basal—weak)
27 78F None In situ SCC Negative ND 1 1 +ve (basal)
28 87M None In situ SCC Negative ND 1 3 +ve (basal)
29 88M None In situ SCC Negative ND 1 3 −ve (throughout)
30 58M None In situ SCC Negative ND 1 3 Patchy
31 51F None In situ SCC Negative − (RNA
degraded)
3 2 −ve (basal)
Dysplasia
32 81F None Moderate
dysplasia
Negative − 1 2 +ve (basal)
33 79F None Mild and
moderate
dysplasia
Negative − 1 2 +ve (basal)






Negative − 1 2 +ve (basal)
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role of ‘deregulated E7 expression’ in stimulating this
protein during HPV carcinogenesis. A correlation between
p16INK4a expression and HPV DNA-positivity was not
apparent in the mild and moderate dysplastic conjunctival
lesions, which might suggest HPV DNA presence, rather
than any overt causal association. Of the four HPV 16
DNA-positive cases, one (case 41) was a squamous meta-
plasia, and contained only discrete p16INK4a -positive cells.
This is also observed during cervical metaplasia, and was
classified as ‘p16INK4a -negative’ in line with published
criteria [22]. The remaining three HPV DNA-positive cases
of conjunctival dysplasia (cases 36, 37, and 39) were MCM-
positive in the lower half of the epithelium, and TP53-
positive in basal cells or throughout the epithelium, an
ambiguous pattern that does not support HPV causality.
While there is a broadly similar pattern of biomarker
expression in HPV-driven conjunctival in situ squamous
carcinoma, the lower-grades of conjunctival dysplasia
group is heterogeneous, a situation which may reflect their
diverse origins.
Markers of the productive HPV life cycle
In contrast to MCM and p16INK4a, markers that allow
visualisation of the productive stages of the HPV life cycle
are usually expressed in a limited number of surface-
proximal epithelial cells in high-grade lesions (e.g. cervical
high-grade squamous-intraepithelial lesions). In cervical
low-grade squamous-intraepithelial lesions E4 is very
highly expressed and coincides with the onset of viral
genome amplification [17]. As expected, the majority of the
HPV DNA-positive conjunctival in situ squamous carci-
noma cases were HPV E4-negative. One case was found
with a characteristic pattern of E4 in a small number of cells
close to the epithelial surface (see Fig. 3a, c). Curiously, E4
expression was not seen in the four conjunctival dysplasia
cases, suggesting that like the oropharynx and the endo-
cervix, the conjunctiva may not be an epithelial site where
productive HPV infection is supported. In fact, the absence
of E4 in these low-grade lesions, when considered alongside
the presence of TP53, and the absence of p16INK4a, prompts
re-interpretation of the HPV DNA-positive result in these
lesions.
Detection of HPV transcription in conjunctival
in situ squamous carcinoma and dysplasias
The detection of HPV DNA in cases showing biomarker
patterns pathognomonic of viral neoplasia leads us to
suspect a causal association between HPV infection and
the development of a subset of conjunctival in situ
squamous carcinoma. Cellular biomarkers such as those
used in this study can however be deregulated
in situations other than HPV infection, prompting us to
look more directly at the contribution of HPV16 E6 and
E7. Unlike the HPV E4 protein, which is abundantly
expressed during productive infection, the E6 and E7
gene products are expressed at only low levels, and are
not routinely detected using immunostaining approaches.
To overcome this, the 13 carcinoma in situ samples that
were HPV 16 DNA-positive by whole tissue section-
PCR, as well as all the conjunctival lower grades of
dysplasia biopsies and four of the HPV DNA-negative
in situ squamous carcinoma cases, were screened for viral
gene expression using an RNAscope in situ methodology.








HPV RNA P16 MCM TP53 E4 Lymphocytic
infiltration
35 21F None Moderate
dysplasia
Negative − 1 2 +ve (basal)
36 55F None Mild and
moderate
dysplasia
HPV 16 − 1 2 +ve (basal)
37 78M None Moderate
dysplasia
HPV 16 − 1 2 +ve (basal)
38 74M Eczema Mild dysplasia Negative − 1 2 +basal
39 61M None Moderate
dysplasia
HPV 16 − 1 2 +ve (throughout)
40 76M None Moderate
dysplasia
Negative − 1 2 +ve (throughout)
41 65M None Squamous
metaplasia
HPV 16, 6 − 1 2 +ve (basal)
HPV DNA and RNA analysis of the conjunctival in situ squamous carcinoma and dysplasias examined in this study, along with biomarker and
histological phenotype. HPV DNA-positive cases are highlighted in bold
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housekeeping gene probe, in order to identify any that
may have generally poor RNA integrity, and thus be
unsuitable for such analysis. All the sections showed
evidence of housekeeping gene expression throughout the
epithelial layers (although case 31 showed some
degradation in early sections), indicative of intact RNA,
and in these cases, the extent of HPV16 E6/E7 gene
expression was subsequently assessed. In order to sub-
stantially improve the signal-to-noise ratio of RNA ISH,
RNAscope® employs a probe design strategy much akin
Fig. 2 Differences in biomarker expression in HPV DNA-positive and
-negative conjunctival in situ squamous carcinoma. a Conjunctival
in situ squamous carcinomas positive for HPV DNA were subject to
conventional H&E staining (left panel), or were stained for p16INK4a by
immunohistochemistry (brown), or for TP53 (green) or MCM (red)
using an immunofluorescence approach (IF (rightmost panels)). Nuclei
are counterstained using DAPI in the IF images. The majority of HPV
DNA-positive conjunctival in situ squamous carcinomacases were
p16INK4a-positive, TP53-negative and MCM-positive. A junctional
region is present in case 3, which is marked by an abrupt p16INK4a
boundary. TP53 was absent in the lesional area, but was present in the
adjacent ‘normal’ epithelium (inset). b Examples of HPV DNA-
positive, p16INK4a-positive cases that were also TP53-positive, but
MCM-negative were also observed. In these cases, widespread lym-
phocytic infiltration was apparent as shown in the H&E enlargement
inset. c Conjunctival in situ squamous carcinoma cases negative for
HPV DNA, are typically negative for p16INK4a, and variably positive
for TP53 and MCM. In a, b and c, different cases are shown in panels
(i) and (ii). Details of the cases shown in (a−c) are outlined in Table 1.
The position of the epithelial basal lamina is shown in the left most
images as a dotted line
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to fluorescence resonance energy transfer (FRET), in
which two independent probes (double Z probes) have to
hybridise to the target sequence in tandem in order for
signal amplification to occur. As it is highly unlikely that
two independent probes will hybridise to a non-specific
target right next to each other, this design concept ensures
selective amplification of target-specific signals. For each
target RNA species, ~20 double Z target probe pairs are
designed to specifically hybridise to the target molecule,
but not to non-targeted molecules. Each target Z probe
contains three elements: The lower region of the Z is an
18- to 25-base region that is complementary to the target
RNA. This sequence is selected for target-specific
hybridisation and uniform hybridisation properties. A
spacer sequence links the two components of the probe.
The upper region of the Z is a 14-base tail sequence. The
two tails from a double Z probe pair forms a 28-base
binding site for the pre-amplifier. The HPV 16 E6/E7
probe recognises sequences between bases 84 in E6 and
753 of E7. Although this region extends beyond
nucleotide 670, transcripts originating from the late
promoter (P670) are not detected, as only a single ZZ pair
is contained within this region (≥3 ZZ pairs (i.e. 150 bp)
required for RNAscope signal (https://acdbio.com)).
Initial staining was carried out with chromogenic devel-
opment on case 8 (Fig. 3b), which was HPV DNA-
positive, had a pathognomonic biomarker expression
pattern, and contained several small areas where viral E4
expression was found. As expected, this lesion showed
extensive HPV16 E6/E7 expression throughout the epi-
thelium, with a clear elevation in E6/E7 abundance in
regions of E4 positivity (Fig. 3c), which fits well with the
established life cycle role of E6, E7 and E4 in HPV
genome amplification. Indeed, a similar but more dra-
matic upregulation of viral gene expression is typical of
productive HPV16 infections, as seen following recon-
struction of the HPV16 life cycle in organotypic raft
culture (Fig. 4a). Basal and suprabasal E6/E7 expression,
often with some degree of E6/E7 elevation towards the
epithelial surface, was clearly evident in 11/13 (85%) of
the conjunctival in situ squamous carcinomacases that
were HPV 16 DNA-positive (Table 2, Fig. 4b, c). The
two HPV DNA-positive cases that failed to show an E6/
E7 RNAscope signal also failed to show the classical
biomarker pattern typically associated with HPV-induced
neoplasia, and most notably were not associated
with elevated p16INK4a expression (see Table 2). In the-
se cases, we suspect that HPV DNA is present either as a
subclinical infection adjacent to the in situ squamous
Fig. 3 Expression of HPV E4 protein can occur in conjunctival HPV
infections. a One conjunctival in situ squamous carcinoma case (case
8) showed sporadic expression of the HPV E4 protein (green
(arrowed)), which could be visualised by IF in cells close to the epi-
thelial surface. The cell nuclei were counterstained with DAPI. b HPV
E6/E7 expression was apparent in this lesion following RNA scope
analysis, with an elevation of expression in sporadic cells close to the
epithelial surface (arrowed). c (i) Cells showing elevated E6/E7
expression, also expressed E4 in this lesion (arrowed), which indicates
that progression through the papillomavirus life cycle is occurring in
these cells. The difference in the intensity of signal between the basal/
parabasal (ii) and suprabasal/superficial (iii) cell layers is shown at the
bottom of the figure in the enlargement panels. The position of the
basal lamina is shown as a dotted line
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carcinoma tissue, or that HPV DNA or HPV virions
are present in the sample in the absence of an active
infection.
Because high-grade cervical neoplasia can arise from
productive low-grade neoplasia, the lower grades of dys-
plasia biopsies were also examined in the same way. In this
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case, none of the four HPV DNA-positive biopsies showed
evidence of viral gene expression using the in situ RNA-
scope approach (Table 2), as did none of the HPV DNA-
negative in situ squamous carcinoma cases. In carrying out
these studies, we noted that tyramide development followed
by fluorescence visualisation of the RNAscope signal
offered a significant sensitivity increase (see Fig. 4a centre
and rightmost panels), particularly when visualising viral
gene expression in the carcinoma cases (Fig. 4d), as can be
seen when the images shown in Fig. 4c are compared with
those shown in Fig. 4d. Although several attempts were
made to show evidence of HPV gene expression amongst
the HPV DNA-positive dysplasia, we were unable, even
using this fluorescence approach, to generate any convin-
cing E6/E7 signals in these lesions (see Fig. 4d (iii)). We
assume that the levels of viral gene expression are either at
the limits of sensitivity using this approach, or more likely,
that the conjunctival dysplasia examined here, are not
causally associated with HPV. The absence of p16INK4a
expression in these dysplastic lesions is compatible with this
assumption. Interestingly, we were not able to detect HPV
DNA in these biopsies using an in situ hybridisation
approach, despite being able to localise HPV16 genomes to
the nuclei of infected cells in the conjunctival in situ
squamous carcinomacases (Fig. 5). In these lesions, the
distribution of HPV DNA-positive cells was similar to that
observed using the RNAscope approach (Fig. 5a), with the
diffuse nuclear pattern suggesting the presence of episomal
HPV genomes. As with the RNAscope result, an elevated
signal was apparent in some cells close to the epithelial
surface, which fits well with the modest amplification of
viral genomes expected in these lesions.
Discussion
Although several studies have suggested that conjunctival
in situ squamous carcinoma may have an association with
HPV, most reports have been restricted to the detection of
HPV DNA by PCR analysis, and have not yet confirmed
active viral infection or HPV causality. Indeed, HPV DNA
may be present either as a passenger virus or as a subclinical
infection in adjacent normal tissue, which can lead to a
positive result in a tumour biopsy. The detection of HPV in
urine samples, which is sometimes used as an indication of
the presence of cervical neoplasia [23], is a clear example
that illustrates the sensitivity of HPV DNA detection
methods, and the caution required in interpreting a positive
result. To prove causality, the presence of viral mRNA or
viral proteins, and a demonstration of their phenotypic
consequences at the site of infection is required—with
infection-biomarkers allowing visualisation of the cellular
changes that may eventually contribute to the tumourogenic
state. In this study we have combined DNA typing, with
classical immunohistochemistry to detect viral proteins and
surrogate markers of virus infection. In the majority of the
conjunctival in situ squamous carcinomas examined here,
such markers were closely associated with active HPV E6/
E7 transcription, and with the well-established pathogno-
monic changes that are typically associated with the
development of HPV-driven cancer.
The primary aim of our study was to examine the causal
association between high-risk HPV and conjunctival in situ
squamous carcinoma, rather than to provide information on
the incidence of the disease. Only one high-risk HPV type was
detected amongst our collection of conjunctival biopsies. The
limited HPV diversity seen in the conjunctival in situ squa-
mous carcinoma cases has some parallels with what has been
reported at the oropharynx and endocervix, where HPV16,
and only a small number of other HPV types cause the vast
majority of the cancers. As no single biomarker can be used to
establish HPV causality, we performed a combination of
biomarker stains to help confirm HPV involvement. In most
of the HPV DNA-positive conjunctival in situ squamous
carcinomas, immunohistochemistry revealed extensive
p16INK4a and MCM expression, along with an absence of
TP53 in the epithelial basal layer. The HPV E4 protein was
not detected in the majority of biopsies examined, similar to
what is seen in cervical high-grade squamous-intraepithelial
lesions, where the virus is undergoing an abortive rather than a
productive life cycle. Only in one of the conjunctival in situ
squamous carcinoma cases was expression of the HPV E4
Fig. 4 HPV transcription in conjunctival in situ squamous carcinoma is
characteristic of abortive infection. a The productive HPV life cycle can
be supported in organotypic raft culture of HPV-infected epithelial cells.
HPV16 raft organisation is shown in the left most panel, with the ‘basal
lamina’ marked by a dotted line. E6/E7 transcripts were detected in
adjacent sections using immunohistochemistry (brown; centre panel), or
immunoflourescence (green; right panel) methodology. The upper arrow
in both panels indicates the elevation in expression that accompanies
viral genome amplification in the mid epithelial layers, which persists
towards the epithelial surface depending on the extent of epithelial
terminal differentiation. The lower arrow shows that E6/E7 gene
expression occurs in the basal and parabasal cell layers during productive
infection. b H&E staining of three of the conjunctival in situ squamous
carcinomacases to show the regions that are enlarged in the E6/E7
RNAscope stains illustrated in (c). c Detection of HPV E6/E7 tran-
scription is revealed by the presence of brown spots in the cytoplasm and
nucleus (arrowed in (i)−(iii)). In b, c and d, different cases are shown in
panels (i), (ii) (iii) and (iv). Case 3, shown in (i), includes a junction
between infected epithelium and normal epithelium. Some elevation in
E6/E7 expression towards the epithelial surface is apparent in case 3, but
is more obvious in case 11 (iii). An enlargement of the surface epithelial
layers and the basal/parabasal layers is shown in the lower boxes in (iii).
d Immunofluorescent detection of the E6/E7 RNAscope signal shows
viral gene expression more conclusively. The junction between infected
and normal epithelium is apparent in Case 3 (i). Uniform E6/E7
expression throughout the epithelial layers is apparent in case 4 (ii). No
E6/E7 expression was apparent in any of the conjunctival dysplasias,
with the results shown for Case 38 shown in (iii)
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protein detected in a limited number of cells towards the
epithelial surface. HPV activity within the conjunctival in situ
squamous carcinoma tissue was further confirmed by HPV
transcriptional analysis using an RNA in situ staining
approach (RNAScope—ACD, Newark, California). In sup-
port of the above, HPV16 E6/E7 transcripts were apparent
throughout the neoplastic epithelium, and stopped abruptly at
the boundary with the normal uninfected epithelium (Fig. 4).
In the one conjunctival in situ squamous carcinoma case that
was HPV E4-positive, E4 expression was restricted to a few
cells close to the epithelial surface that showed extensive HPV
E6/E7 viral gene expression, compatible with limited initiation
of the late phase of the papillomavirus life cycle. Apart from
this case, only a very limited increase in HPV E6/E7 tran-
scription (and viral DNA abundance) was seen in the upper
epithelial layers, when compared to HPV16 DNA-positive
organotypic rafts, supporting the conclusion that conjunctival
epithelium is primarily a site of abortive rather than productive
HPV16 infection. The rise in E6/E7 RNAscope spot density
close to the epithelial surface in some lesions (Fig. 4) may
reflect the different dynamics of cells at the conjunctival sur-
face, although this is also seen sometimes in cervical high-
grade squamous-intraepithelial lesions.
As we have detected only one lesion that expressed both
the HPV E4 and E6/E7 genes in the mid epithelial layers (the
Wing cells) of the conjunctiva, we postulate that productive
low-grade lesions may occur rarely at conjunctival sites, and
that such low-grade lesions may not be necessary precursors
in the development of conjunctival in situ squamous carci-
noma. The term carcinoma in situ is now encompassed within
the wider term high-grade squamous-intraepithelial lesions,
and at the cervix, is generally regarded as a precursor of
invasive cervical cancer [24]. Our current thinking is that
high-grade squamous-intraepithelial lesions can arise at the
endocervix without preceding low-grade squamous-intrae-
pithelial lesions, and that a similar situation may account for
the absence of clear precursor lesions that predict the presence
of oropharyngeal cancer. In both cases, the particular orga-
nisation of the epithelial site where infection occurs is thought
to influence viral gene expression and the neoplastic pheno-
type, with high-grade squamous-intraepithelial lesions being
an immediate consequence of virus infection at these sites. As
with the tonsils and the endocervix, it seems likely that the
conjunctival epithelium may be an epithelial site where viral
gene expression is deregulated from the outset. Further
investigation of this epithelial site may help us to understand
Fig. 5 Detection of HPV DNA by in situ hybridisation. a HPV DNA is
apparent in lesions showing evidence of HPV transcriptional activity
in the E6/E7 RNAscope analysis shown in Fig. 3 (case 6 (i) and case 3
(ii) shown). Signal intensity was either uniform across the full thick-
ness of the epithelium (i), or showing some evidence of increase in
signal intensity towards the epithelial surface (ii). b Typical in situ
hybridisation patterns seen in low-grade cervical neoplasia, where
some degree of genome amplification is apparently close to the epi-
thelial surface (i), and in high-grade cervical neoplasia (ii) associated
with HPV genome integration
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the more rapidly progressing high-grade dysplasia at the
cervix that can lead to cancer within a few years rather than
through a long-term stepwise progression over decades.
Interestingly, Scott et al. [25] also suggested an active role for
HPV in conjunctival squamous carcinoma, using a PCR
(rather than an in situ)-based methodology to detect viral
DNA and RNA, although in their case they found positivity in
all conjunctival squamous carcinomas. The in situ approach
described here support these findings, but suggest that HPV
causality extends to only a subset of such lesions, and that
these can be characterised by a characteristic pattern of bio-
marker expression. Interestingly, we also detected three HPV
DNA-positive in situ carcinomas with extensive p16INK4a and
MCM expression, which were TP53-positive throughout the
epithelium. Initially these were thought not to be associated
with HPV expression, however they were HPV E6/E7
RNAScope-positive, although with limited expression com-
pared to other HPV DNA-positive conjunctival high-grade
squamous-intraepithelial lesions. Upon further examination of
the haematoxylin and eosin-stained biopsies we found
breakdown of the basal membrane, and extensive lympho-
cytic infiltration, suggesting some degree of immune control,
and an inhibition of viral activity. Indeed, declining HPV E6
expression, as seen by RNAScope transcript mapping, might
be expected to reduce the proteosomal degradation of TP53,
with p16INK4a and p14ARF rising as a consequence, depending
on the cellular microenvironment.
The association between conjunctival in situ squamous
carcinoma and atopy has been previously reported by sev-
eral groups [3, 26, 27]. Rundle et al. [26] noted that rela-
tively young immunocompetent patients present with
aggressive disease that is sometimes bilateral and recurrent.
There may be several explanations. Atopy is characterised
by an allergen-induced elevation of IgE levels that is
mediated by a type-2 helper T lymphocyte (Th2 cells)
response, with atopic individuals undergoing an exag-
gerated response following antigen exposure. Although
type-2 responses predominate in neonates, there is usually
an immune switch in favour of type-1 responses in normal
adults, which supports cell-mediated immunity active
against virus-infected and neoplastic cells [28]. As this
switch does not occur in atopes, this may explain in part
their vulnerability to HPV-infection. Alternatively, changes
in barrier proteins such as filaggrin, or the presence of
mutations seen in atopic dermatitis, may compromise con-
junctival epithelial barrier function [29]. There is also an
inverse relationship between the expression of Claudin 1 in
tight junctions of the epidermis, and the development of a
Th2 response, which suggests that this protein may affect
the immune response to putative environmental allergens
[30]. Reduced expression of several anti-microbial peptides,
including a cathelicidin-LL37 and β-defensin, has also been
reported to predispose to skin infections in atopic dermatitis
[31], along with diminished recruitment of innate immune
cells (neutrophils, plasmacytoid dendritic cells, and natural
killer cells) which are a critical source of the antiviral type 1
Interferons [32], may further contribute to the susceptibility
of atopic individuals to infection.
In this study, the HPV 16-positive atopic group had a
higher rate of disease resistance to primary treatment and
higher recurrences compared to non-atopic cases that did not
harbour HPV16. Secondly, many of the tumours in the atope
group affected the medial, inferomedial, inferior forniceal
and inferior tarsal conjunctiva. This is quite different to the
classical ultraviolet-induced conjunctival squamous neopla-
sia that occurs in the sun-exposed conjunctiva at the medial
limbus that is often leukoplakic, apparent in the non-atopic
group. Whilst speculative, it is possible that atopes may be
rubbing their eyes excessively due to the activation of the
itch cycle, which is classically induced by cytokine release
from eosinophils. In support of this, many of the biopsies
from the atopes contained eosinophils. As eye rubbing tends
to focus pressure on the medial lower eyelids, it is plausible
that the conjunctiva beneath the medial eyelids (medial
bulbar, inferior formiceal and inferior tarsal) is being
exposed to microtrauma. In support of this proposal, Gichuhi
et al. identified micro abrasions of the conjunctival surface
caused by vitamin A deficiency as a risk factor in con-
junctival squamous cell carcinoma in cases from Africa,
potentially allowing HPV to invade the conjunctival epi-
thelial cells [2]. Recently, McGrath et al. recorded their
experience of conjunctival squamous carcinoma in patients
wearing ocular prostheses [33]. They all occurred in the
superior tarsal conjunctiva where the latter was constantly
rubbing against an ocular prosthesis. In three out of four of
the cases, the conjunctival biopsies from the squamous car-
cinoma contained HPV16 DNA (by PCR). They proposed
that ocular prosthesis-induced conjunctival microtrauma
which could be rendering the conjunctiva susceptible to
HPV16 infection and conspiring with the effects of direct
trauma induced metaplasia to trigger conjunctival squamous
carcinoma [33].
At present, it is not known how HPV16 gains access to
the conjunctiva. Possible routes of infection include direct
inoculation, potential spread from the nasopharnyx via the
nasolacrimal duct or haematogenous. The clinical infor-
mation presented in this paper suggests that a combination
of HPV infection and atopy confers an aggressive course,
with more resistance to primary treatment and more recur-
rences compared to non-atopes. However, it was not pos-
sible to fully compare the clinical course between atopes
with HPV 16 and atopes without HPV16 because of the
small number of cases for the latter group.
In summary, the work described here identifies a novel
vulnerable epithelial site where HPV16, the most pro-
blematic high-risk HPV type, causes conjunctival in situ
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squamous carcinoma. As at the cervix and anus, it appears
that conjunctival in situ squamous carcinoma can be
associated with a junctional epithelium. We were able to
find evidence of late gene expression (HPV E4 protein) in
only one case, suggesting that conjunctival in situ squa-
mous carcinoma is most likely, a direct consequence of
viral infection in a subset of patients. The molecular
deficiency that predisposes atopic individuals to infection
and the development of squamous neoplasia warrants
further analysis.
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